Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 68 vaccines in clinical trials on humans, and 20 have reached the final stages of testing. At least 90 preclinical vaccines are under active investigation in animals
Vaccines save millions of lives each year. Vaccines work by training and preparing the body’s natural defences --- the immune system--- to recognize and fight off the viruses and bacteria they target. If the body is exposed to those disease-causing germs later, the body is immediately ready to destroy them, preventing illness.
There are currently more than 50 COVID-19 vaccine candidates in trials. WHO is working in collaboration with scientists, business, and global health organizations through the ACT Accelerator to speed up the pandemic response. When a safe and effective vaccine is found, COVAX (led by WHO, GAVI and CEPI) will facilitate the equitable access and distribution of these vaccines to protect people in all countries. People most at risk will be prioritized. While we work towards rolling out a safe and effective vaccine fairly, we must continue the essential public health actions to suppress transmission and reduce mortality.
The COVID-19 candidate vaccine landscape
The COVID-19 candidate vaccine landscape database compiles detailed information on COVID-19 vaccine candidates in development.
The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET).
The landscape:
- provides summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development;
- provides analysis and visualization for several COVID-19 vaccine candidate categories;
- tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies,
- provides links to published reports on safety, immunogenicity and efficacy data of the vaccine candidates;
- includes information on key attributes of each vaccine candidate; and
- allows users to search for COVID-19 vaccines through various criteria such as vaccine platform, dosage, schedule of vaccination, route of administration, developer, trial phase and clinical endpoints being measured in Phase 3.
Submission of data
All data from independent institutions and vaccine developers are welcome to provide information on vaccine candidates being developed using the information template. Submitted data will be made openly accessible on a regular basis to enable fast data sharing.
Data extraction tools and sources
To ensure the latest information is available, the landscape will be updated twice a week (Tuesday and Friday, 17:00 CET) by searching, gathering and cross-checking data from multiple sources such as the Cochrane vaccine mapping tool, Pubmed, ClinicalTrials.gov, WHO ICTRP and from a network of researchers and industry for new candidate vaccines and screening registered trials for clinical information. Where data is missing, we either do not add any information (blank cells) or we supplement information gathered from press or public releases. We welcome your feedback to help us update or make necessary changes, please note any updates will only be done twice a week.
Disclaimer
These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
Contact us
The R&D Blueprint team is responsible for developing the COVID-19 candidate vaccine landscape database. For questions relating to the collection or sharing of data for novel COVID-19 vaccine candidates
WHO Working Group – Target Product Profiles for COVID-19 Vaccines
Overview
The current global nCoV public health emergency underscores the need to accelerate the development of nCoV candidate vaccines. The Working Group on Target Product Profile for vaccines against COVID-19 aims to provide guidance from an end-to-end perspective. The objectives of this group are
- To develop a global target product profile (TPP) for vaccines against COVID-19.
- The TPP will include preferred and minimally acceptable profiles for two vaccines:
- Human vaccine – for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers.
- Human vaccine – for reactive use in outbreak settings with rapid onset of immunity.
- To prepare and be available for the regular working group calls.
- To provide technical advice and support the WHO Secretariat through comments and or feedback from stakeholders
Comments
Post a Comment
if you have any doubt contact me
rajpitanagamers@gmail.com